Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
JAK inhibitor
Biotech
Aclaris claims ph. 2 win for JAK inhibitor but investors spooked
Aclaris has touted the latest phase 2 results for its “soft” JAK 1/3 inhibitor in atopic dermatitis as a win for the beleaguered biotech.
James Waldron
Jan 10, 2024 8:35am
Lynk hits main goal to wrap up clean sweep of phase 2 JAK trials
Aug 23, 2023 9:55am
Sun's $576M Concert hits bum note as FDA imposes partial hold
May 2, 2023 7:09am
Minghui's phase 2 win for potential Opzelura competitor
Apr 14, 2023 10:35am
Galapagos cleans closet of another 4 programs in CAR-T pivot
Aug 5, 2022 10:03am
GSK inks $2B Sierra takeover, turning $3M bet into big buyout
Apr 13, 2022 7:08am
